Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in...

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rituximab (RTX) biosimilar GP2013 demonstrates comparable clinical efficacy to reference RTX.
• Safety considerations are crucial when switching from reference biologics to biosimilars.

Purpose of the Study:

• To evaluate the safety of switching from reference RTX to RTX biosimilar GP2013 in rheumatoid arthritis (RA) patients.
• To compare safety outcomes between patients switching to GP2013 and those continuing reference RTX.

Main Methods:

• A multinational, randomized, double-blind safety study involving 107 RA patients requiring RTX continuation.
• Patients were randomized to switch to GP2013 or continue reference RTX, with stable methotrexate and folic acid dosages.
• Safety assessments included hypersensitivity, infusion reactions, anaphylaxis, immunogenicity (antidrug antibodies), and general adverse events.

Main Results:

• Low incidences of hypersensitivity (9.4% vs. 11.1%) and infusion-related reactions (11.3% vs. 18.5%) were observed in GP2013 and reference RTX groups, respectively.
• Only one patient developed antidrug antibodies, with no neutralizing antibodies or association with adverse events.
• No clinically meaningful differences in adverse event rates were found between the treatment groups.

Conclusions:

• Switching from reference RTX to the biosimilar GP2013 did not introduce detectable safety risks in RA patients.
• The safety profiles of GP2013 and reference RTX were similar, supporting the safety of switching.